Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Advanced Urothelial and Genitourinary Tumors With DNA-Repair Defects
NCT03375307Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in genitourinary cancer, bladder cancer, sponsored by National Cancer Institute. Started Nov 2020; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
genitourinary cancerbladder cancer
Beyond the preview
Go deeper on NCT03375307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03375307.